Trials / No Longer Available
No Longer AvailableNCT05511350
Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001
An Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- I-Mab Biopharma US Limited · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- —
Summary
This EAP was designed to provide TJ210001 to the remaining subjects with relapsed or refractory solid tumors who were enrolled on the parent study, TJ210001STM101 (NCT04678921), and plan to continue with treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TJ210001 |
Timeline
- First posted
- 2022-08-23
- Last updated
- 2022-10-18
Source: ClinicalTrials.gov record NCT05511350. Inclusion in this directory is not an endorsement.